This product is suitable for use with the?Maxpar? Metal Labeling Kits.?For metal labeling using Maxpar? Ready antibodies,?proceed directly to the step to Partially Reduce the Antibody by adding 100 ?l of Maxpar? Ready antibody to 100 ?l of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar? User Guide when conjugating Maxpar? Ready antibodies.

ELISA Capture^1-5 or ELISPOT Capture⁶: The Ultra-LEAFpurified JES3-9D7 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502) as the detecting antibody and recombinant human IL-10 (Cat. No. 571009) as the standard. The Ultra-LEAF? purified antibody is suggested for ELISPOT capture.
Neutralization^1-3,9: The Ultra-LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. Nos. 501427 & 501428). The JES3-9D7 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Additional reported applications (for the relevant formats) include:?immunohistochemical staining¹².
Note: For testing human IL-10 in serum or plasma, BioLegend's ELISA Max? Sets (Cat. Nos. 430601 & 430606) are specially developed and recommended.

The JES3-9D7 antibody reacts with human and viral interleukin-10 (IL-10).

Maxpar? is a registered trademark of Standard BioTools Inc.

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA Capture, Neut)
2. Gotlieb W, et al. 1992. Cytokine 4:385. (ELISA Capture, Neut)
3. Yssel H, et al. 1992. J. Immunol. 149:2378. (ELISA Capture, Neut)
4. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA Capture)
5. Burdin N, et al. 1993. J. Exp. Med. 177:295. (ELISA Capture)
6. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISPOT Capture)
7. Schaerli P, et al. 2000. J. Exp. Med. 192:1553.
8. Jason J, et al. 1999. Clin. Diagn. Lab Immunol. 6:73.
9. Akdis CA, et al. 1998. J. Clin. Invest. 102:98. (Neut)
10. Stary G, et al. 2011. J. Immunol. 186:103. PubMed
11. Mason GM, et al. 2012. PNAS. PubMed
12. 12. Smith DR, et al. 1994. Am. J. Pathol. 145:18. (IHC)

1. Gadalla R, et al. 2022. STAR Protoc. 3:101643. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. de Waal-Malefyt R, et al. 1992. Curr. Opin. Immunol. 4:314.
3. Howard M, et al. 1992. Immunol. Today. 13:198.
4. Quesniaux V. 1992. Research Immunol. 143:385.